Treatment of polycystic ovary syndrome in rats by kisspeptin

Abstract

The study designed to evaluate influence of kisspeptin on polycystic ovary syndrome in female rats, First experiment (Induction of polycystic ovary): thirtieth virgin female rats divided randomly into two groups first group via used ten rats serves as control group . While the second group twenty female rat (PCOS-induce group) were orally administered with letrozole at a dose of 1 mg/kg/21 days. The Second Experiment Effect of treatments with kisspeptin on PCOS : Animals were divided as follows: first group (negative control) .Second group (Positive control) .While animals in third and fourth groups (PCOS+Kisspeptin): five animal in each group PCOS-induced rats administrated of 20 and 40 nmol/rat S/C 21 days Kisspeptin daily respectively .The result show in first experiment a significant increase in serum activity of LH, FSH, estrogen and testosterone and significant decrease progesteron concentration in serum of female rats treated with letrozole. While in the second experiment there was significant decrease in FSH in the C+ compared with C and PCOS treated group. A significant increase in the LH in C+ compared with C and treated group 20 and 40 nmol/rat Kisspeptin . Also the results showed that there was a significant decrease in serum estrogen concentration was observed in PCOS nontreated group compared with control. On other hand a significant increase in serum estrogen in T1(20 nmol/kg B.W) compared with T2(40 nmol/kg B.W). The results of the histopathological study of ovary after treatment PCOS with kisspeptin 20 nmol/kg show partial return of follicular cyst to normal ovarian tissue, but the treated with 40 nmol/kg show semicomplete treated and return follicular cyst to normal ovarian tissue. On conclusions, the present study confirmed that PCOS affect the female reproductive hormonal balance and kisspeptin 40 nmol/rat daily S/C injection show effect in normal restoring of female reproductive hormonal and histological balance of PCOS rats.